Komori
Share Issuance and Disposal4893Noile-Immune Biotech Inc.Pharmaceuticals

Notice of Completion of Payment for the Issuance of Noile-Immune Biotech Inc.’s 14th Stock Acquisition Rights (with Provisions for Revision of the Exercise Price) through a Third-Party Allotment

Payment of the issue price by the allottee has been completed for the stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment. The stock acquisition rights may be exercised in the future, and the exercise price will be adjusted in line with the share price.

Worth reading
67In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1400000
Japanese yen (total issue price)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price through a Third-Party Allotment

Who receives how much

Potential shares: 10,000,000 (100,000 stock acquisition rights, with 100 shares per stock acquisition right)

Okasan Securities Co., Ltd. (100,000 stock acquisition rights)

The lower thin line represents the existing number of shares to which these shares will be added.

¥14 per stock acquisition right
Total issue value

¥1,400,000

Amount of funds to be raised
¥1,349,400,000 (estimated net proceeds). The actual amount raised will vary depending on the exercise price and other factors.
Terms of the stock acquisition rights
Exercise price
Initial exercise price: ¥136. Subject to an adjustment clause. Minimum exercise price: ¥81; no maximum exercise price.
Exercise period
From 6 October 2026 (the bank business day following the allotment date) through 5 October 2028
Number of Stock Acquisition Rights
Total issued: 100,000. Unexercised balance: Not disclosed
Offering structure
Underwriter / lead underwriter
Okasan Securities Co., Ltd.
Intended allottee's holding policy
The transfer of these stock acquisition rights requires approval from the Company's Board of Directors. The Company will be subject to a lock-up on the issuance of shares or other securities until the date 180 days after the date of execution of the third-party allotment agreement.
Payment date
5 October 2026
Basis for determining the amount to be paid
The initial exercise price is the closing price on the Tokyo Stock Exchange on the trading day immediately preceding the date of the issuance resolution. The specific closing price is not stated in this document. The revised exercise price will be 95% of the closing price on the Tokyo Stock Exchange on the trading day immediately preceding the adjustment date, rounded down to the nearest yen.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price through a Third-Party Allotment
Number of shares to be issued or disposed ofPotential shares: 10,000,000 (100,000 stock acquisition rights, with 100 shares per stock acquisition right)
Issue price and disposal price¥14 per stock acquisition right
Total issue value¥1,400,000
Amount of funds to be raised¥1,349,400,000 (estimated net proceeds). The actual amount raised will vary depending on the exercise price and other factors.
Payment date5 October 2026
Intended allotteeOkasan Securities Co., Ltd. (100,000 stock acquisition rights)
Intended allottee's holding policyThe transfer of these stock acquisition rights requires approval from the Company's Board of Directors. The Company will be subject to a lock-up on the issuance of shares or other securities until the date 180 days after the date of execution of the third-party allotment agreement.
Basis for determining the amount to be paidThe initial exercise price is the closing price on the Tokyo Stock Exchange on the trading day immediately preceding the date of the issuance resolution. The specific closing price is not stated in this document. The revised exercise price will be 95% of the closing price on the Tokyo Stock Exchange on the trading day immediately preceding the adjustment date, rounded down to the nearest yen.
Exercise priceInitial exercise price: ¥136. Subject to an adjustment clause. Minimum exercise price: ¥81; no maximum exercise price.
Exercise periodFrom 6 October 2026 (the bank business day following the allotment date) through 5 October 2028
Number of Stock Acquisition RightsTotal issued: 100,000. Unexercised balance: Not disclosed
Underwriter / lead underwriterOkasan Securities Co., Ltd.
Items this document does not state (15)
Estimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Payment of the total issue price has been completed for the 14th stock acquisition rights based on the resolution of the Board of Directors dated 18 September 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the Issuance of Noile-Immune Biotech Inc.’s 14th Stock Acquisition Rights (with Provisions for Revision of the Exercise Price) through a Third-Party Allotment | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori